Skip to content

A Clinical Study on the Treatment of Cancerous Pain and Safety in Cancer Patients by Intrathecal Injection of Dexmedetomidine Combined with Butorphanol

A Clinical Study on the Treatment of Cancerous Pain and Safety in Cancer Patients by Intrathecal Injection of Dexmedetomidine Combined with Butorphanol

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114254
Enrollment
Unknown
Registered
2025-12-09
Start date
2026-01-01
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancerous pain

Interventions

Butorphanol+Dexmedetomidine:Intrathecal injection of butorphanol and dexmedetomidine
morphine:Intrathecal morphine injection

Sponsors

Shandong Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with cancer pain (TNM stage ?~?) were intended to receive intrathecal analgesia; 2. Patients >=18 years old, regardless of gender; 3. Body mass index (BMI) 18.5-30kg /m^2; 4. American Society of Anesthesiologists (ASA) grade I to III; 5. The dose of oral morphine was >200 mg every 24 hours, and the visual analogue scale (VAS) score was >=4 points; 6. Patients and their families were informed of this study and signed informed consent;

Exclusion criteria

Exclusion criteria: 1. Patients who refuse to participate in the trial or who are uncooperative and unable to communicate; 2. Have a history of serious heart, brain, lung, liver, kidney and metabolic diseases; 3. Patients with a history of recovery from abnormal surgical anesthesia; 4. Electrocardiogram: heart rate 180mmHg and/or diastolic blood pressure >110mmHg in hypertensive patients, or <90/60mmHg in hypotensive patients; 7. People with neuromuscular system diseases or mental diseases; 8. Anemia patients; 9. Suspected abuse of narcotic analgesics or sedatives; 10. Predict that difficult airway may occur or have occurred; 11. Known allergy to emulsions and opioids; 12. Researchers consider it inappropriate to participate in this experiment;

Design outcomes

Primary

MeasureTime frame
Pain score;

Secondary

MeasureTime frame
Blood pressure (BP), heart rate (HR), pulse oxygen saturation (SpO2), end expiratory partial pressure of carbon dioxide (PETCO2), respiratory rate (RR) ;Safety evaluation indicators: incidence of nausea, vomiting, itching, drowsiness, hypotension, hypoxemia, respiratory depression, apnea, bradycardia, etc.;Satisfaction rating;Spitzer quality of life index;

Countries

China

Contacts

Public ContactLin Xiaowen

Shandong Provincial Hospital

remember_11@163.com+86 531 68778328

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026